Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STARTER-NET
jRCT1031200023Phase 3Active, not recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- May 2020
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Gastroenteropancreatic Carcinoid Tumor comparing Everolimus monotherapy with Everolimus + lanreotide (2 arms). Primary endpoint: progression-free survival. Started May 2020; status: active, not recruiting.
02
Drugs
everolimuslanreotide
03
Conditions
Gastroenteropancreatic Carcinoid Tumor
Beyond the preview
Go deeper on jRCT1031200023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031200023.